HOME >> MEDICINE >> NEWS
Dasatinib shows high early response rate as first treatment for chronic myelogenous leukemia

CHICAGO - An established second-line drug for chronic myelogenous leukemia has high response rates when given to newly diagnosed patients as their first therapy for the disease, according to early results from a Phase II clinical trial at The University of Texas M. D. Anderson Cancer Center.

"Patients taking dasatinib achieve complete cytogenetic response - absence of the mutated protein that drives this disease - more rapidly than we've observed historically using the current front-line therapy. Side effects are very manageable," says Ehab L. Atallah, M.D., lead author of the study and a fellow in M. D. Anderson's Department of Leukemia. Atallah presented study results at the annual meeting of the American Society of Clinical Oncology in Chicago Saturday June 2nd, 2007. The clinical trial remains in progress with 35 patients enrolled.

Dasatinib, known commercially as Sprycel and produced by Bristol-Myers Squibb, was approved by the U.S. Food and Drug Administration a year ago for use by patients whose disease is unresponsive to or becomes resistant to the front-line therapy imatinib. Both drugs bind to and block a genetically flawed protein known as BCR-ABL, which causes the disease. Atallah explains that dasatinib binds to both forms BCR-ABL while imatinib blocks only one.

"Our hypothesis is that treating with dasatinib first will produce an earlier response, which may translate to a better overall survival," Atallah says. "We haven't proved that here, but these early results are encouraging."

Atallah and colleagues evaluated 35 patients who enrolled in the clinical trial between November 2005 and December 2006. Patients receive either 100 mg of dasatinib once daily or 50 mg twice daily.

Thirty four patients had been on the clinical trial for at least three months when Atallah and lead researcher Jorge Cortes, M.D., professor in the Department of Leukemia, evaluated their data. They found that 77 percent of pati
'"/>

Contact: Laura Sussman
lsussman@mdanderson.org
832-264-8893
University of Texas M. D. Anderson Cancer Center
2-Jun-2007


Page: 1 2

Related medicine news :

1. New study shows promise in reducing surgical risks associated with surgical bleeding
2. Most seniors now have drug coverage, U-M study shows
3. Wireless technology shows promise in diagnosing pediatric intestinal disease
4. Study shows radiofrequency ablation highly effective in treating kidney tumors
5. Method shows promise for early detection of pancreatic cancer
6. Organic farming can feed the world, U-M study shows
7. New study shows Rescue Remedy is an effective all-natural stress, anxiety reliever
8. Borderline personality disorder shows improvements with intensive psychotherapy
9. New drug shows promise in treatment of advanced thyroid cancer
10. Study shows Diachrome improves blood sugar control in people with type 2 diabetes
11. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/22/2017)... ... , ... “Fruit of the Spirit: “Love””: a delightful adventure of two ... “Fruit of the Spirit: “Love”” is the creation of published author, Halimah Jones, who ... five. Halimah is an avid writer, her inspiration for “Fruit of the Spirit: “Love”” ...
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... preserve fertility and create life. Although frozen embryos have a slight statistical advantage ... , “Egg freezing is a wonderful opportunity for women undergoing medical treatment or ...
(Date:9/21/2017)... FL (PRWEB) , ... September 21, 2017 , ... 38-Year-Old ... Aesthetic Surgery Center in Naples, Florida is pleased to announce that Plastic Surgeon Kiranjeet ... Top 40 Under 40 is an annual award that was started in ...
(Date:9/21/2017)... CA (PRWEB) , ... September 21, 2017 , ... ... lunch and learn with Infinity Behavioral Health Services for professionals in the addiction ... a Commercial Payer Audit . , Insurance companies and state and federal ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... communities, nine governmental public health departments have been awarded five-year accreditation status through ... that the benefits of being served by a PHAB-accredited health department now ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... 2017 NuvoAir (formerly called Pond Healthcare ... a partnership with Novartis Pharma AG to distribute NuvoAir,s spirometry ... the leading mobile spirometry platform and Novartis, commitment to address ... ... ...
(Date:9/6/2017)... TORONTO , Sept. 6, 2017 /PRNewswire/ ... new knowledge and skills while treating their ... for hands-on experience without involving patients. Simulation ... skills. Clinicians can carry out procedures, refine ... at risk. Integration of new technology, such ...
(Date:9/5/2017)... , Sept. 5, 2017 Sapheneia and ... DoseCheck solution. Scannerside DoseCheck is a third-party Vendor neutral ... CT scanners and allows compliance with current MITA standards. ... proprietary XR 29 DoseCheck solution is specifically designed to ... alerts of potential radiation doses over a predefined threshold. ...
Breaking Medicine Technology:
Cached News: